MacroGenics (NASDAQ:MGNX - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued on Sunday, Wall Street Zen reports.
Other analysts have also recently issued reports about the company. B. Riley Financial increased their price objective on MacroGenics from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Monday, August 17th. Weiss Ratings cut MacroGenics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday. Finally, Citigroup began coverage on MacroGenics in a report on Friday, October 23rd. They set a "positive" rating on the stock. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $8.50.
Get Our Latest Stock Analysis on MGNX
MacroGenics Trading Down 1.0%
Shares of MGNX opened at $1.96 on Friday. The company's fifty day simple moving average is $3.12 and its 200-day simple moving average is $3.44. MacroGenics has a twelve month low of $1.32 and a twelve month high of $5.08. The company has a market cap of $125.26 million, a P/E ratio of -2.42 and a beta of 1.33.
Hedge Funds Weigh In On MacroGenics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wasatch Advisors LP raised its holdings in MacroGenics by 29.4% during the second quarter. Wasatch Advisors LP now owns 2,018,881 shares of the biopharmaceutical company's stock worth $9,327,000 after purchasing an additional 459,180 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of MacroGenics during the second quarter worth approximately $626,000. Bank of America Corp DE grew its position in shares of MacroGenics by 30.7% during the first quarter. Bank of America Corp DE now owns 2,401,814 shares of the biopharmaceutical company's stock worth $6,941,000 after acquiring an additional 564,094 shares during the last quarter. BlackRock Inc. acquired a new position in shares of MacroGenics in the 2nd quarter valued at $21,618,000. Finally, Pinnacle Associates Ltd. increased its holdings in shares of MacroGenics by 154.7% in the 3rd quarter. Pinnacle Associates Ltd. now owns 647,713 shares of the biopharmaceutical company's stock valued at $2,500,000 after acquiring an additional 393,412 shares during the period. 96.89% of the stock is owned by institutional investors and hedge funds.
MacroGenics Company Profile
(
Get Free Report)
MacroGenics, Inc. is a biotechnology company focused on discovering and developing antibody-based medicines, primarily for cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company works on its own drug candidates and collaborates with other pharmaceutical and biotechnology companies. Its research uses antibody-engineering technologies, including platforms designed to engage immune cells against tumors and to deliver therapeutic payloads to cancer cells. MacroGenics' portfolio has included margetuximab, marketed as Margenza, an antibody treatment approved in the United States for certain patients with HER2-positive metastatic breast cancer.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MacroGenics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list.
While MacroGenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.